The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Anupam Rama - JPMorgan - Analyst
: Yeah. Thanks, Jacob. We have a few minutes for questions. (Conference Instructions)
I just want to start on one question of my own, which is on the Phase 1b PSA response data that you shared just a few minutes ago. It's probably
just a function of small numbers, and I know you're still dose escalating, but it did look like there's a little bit of an inverse dose response, like
anything to comment there? Or is it just a lot of small?
Question: Anupam Rama - JPMorgan - Analyst
: Got it. Okay. The question from the audience. So the portal question is, where will the -- this is related to ORIC-114, where will the clinical trial results
in the second line treatment -- for second line be treated at AACR or ASCO?
Question: Anupam Rama - JPMorgan - Analyst
: And then given amivantamab itself has shown some toxicities. What are the expectations regarding safety when you're using combination
considering the safety profile observed in prior ORIC-114 studies?
Question: Anupam Rama - JPMorgan - Analyst
: Another portal question is what are you looking for competitors in 2025 in the exon 20 space, and I'll throw one in as well, which is maybe speak
to the CNS penetration?
Question: Anupam Rama - JPMorgan - Analyst
: Any questions from the audience? Yes?
Unidentified Analyst
When are you going to be in a position to share data in atypical mutations? And what are your expectations there relative to the efficacies you've
seen in exon 20?
Question: Anupam Rama - JPMorgan - Analyst
: Any final questions from the audience? No? All right. Thank you so much, Jacob.
| 
